Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction: Implications for sexual dysfunction

Drugs

Volumn 68, Issue 2, 2008, Pages 209-229

  Gur, Serap ^a   Kadowitz, Philip J ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

5 alpha reductase inhibitors, therapeutic use; Alpha 1 adrenergic receptor antagonists, therapeutic use; Benign prostatic hyperplasia; Erectile dysfunction therapies, therapeutic use; Erectile dysfunction, treatment

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 [2 (3,4 DIMETHOXYPHENYL)ETHOXY] 2 (4,6 DIMETHOXY 2 PYRIMIDINYLOXY) 3,3 DIPHENYLPROPIONIC ACID; 3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; 3' (2 AMINO 1 HYDROXYETHYL) 4' FLUOROMETHANESULFONANILIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATRASENTAN; BMS 193884; CYCLIC GMP; CYCLO(DEXTRO GLUTAMYLALANYL DEXTRO ALLO ISOLEUCYLLEUCYL DEXTRO TRYPTOPHYL); D 004; DABUZALGRON; DOXAZOSIN; DUTASTERIDE; ENDOTHELIN 1; FINASTERIDE; FR 146687; GUANOSINE PHOSPHATE; IZONSTERIDE; N [2,2,2 TRIFLUORO 1 PHENYL 1 (TRIFLUOROMETHYL)ETHYL] 3 OXO 4 AZA 5ALPHA ANDROST 1 ENE 17BETA CARBOXAMIDE; N [5 (4,5 DIHYDRO 1H IMIDAZOL 2 YL) 5,6,7,8 TETRAHYDRO 2 HYDROXY 1 NAPHTHYL]METHANESULFONAMIDE; NAFTOPIDIL; NITRIC OXIDE SYNTHASE; PROPIVERINE; PYGEUM AFRICANUM EXTRACT; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SABAL EXTRACT; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENERGIC SYSTEM; ASTHENIA; ATHEROSCLEROSIS; BENIGN PROSTATE OBSTRUCTION; BLADDER NECK STENOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIZZINESS; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HEADACHE; HUMAN; HYPOTENSION; IMPOTENCE; ISCHEMIA; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE; MONOTHERAPY; NOCTURIA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATIENT MONITORING; PHYTOTHERAPY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; VASODILATATION;

ERECTILE DYSFUNCTION; HUMANS; IMPOTENCE, VASCULOGENIC; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATE; PROSTATIC HYPERPLASIA; URINARY BLADDER; URINARY BLADDER NECK OBSTRUCTION;

EID: 38149130437     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868020-00005     Document Type: Review

References (134)

1. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824-37
2. Rosen R, Catania J, Pollack L, et al. Male Sexual Health Questionaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777-82
3. Lukacs B. Management of symptomatic BPH in France: who is treated and how? Eur Urol 1999; 36 Suppl. 3: 14-20
4. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999: 281; 537-44
5. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-11
6. Braun MH, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical 'Aging Male' symptoms? Results of the 'Cologne Male Survey'. Eur Urol 2003; 44: 588-4
7. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569-5
8. El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: analysis of risk factors. J Sex Med 2006; 3: 144-9
9. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-49
10. McVary KT, Foley J, Bautista O, et al. The association of lower urinary tract symptoms (LUTS) with sexual function in men participating in a clinical trial of medical therapy for benign prostatic hyperplasia [abstract]. J Urol 2003; 169 Suppl. 322: A1252
11. Vallancien G, Emberton M, Harving N, et al. Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257-61
12. Bruschini H, Schmidt RA, Tanagho EA. The male genitourinary sphincter mechanism in the dog. Invest Urol 1978; 15: 284-7
13. Smith ER, Lebeaux MI. The mediation of the canine prostatic secretion provoked by hypogastric nerve stimulation. Invest Urol 1970; 7: 313-8
14. Burnett AL. Nitric oxide control of lower genitourinary tract functions: a review. Urology 1995; 45: 1071-83
15. Abrams P. Benign prostatic hyperplasia has precise meaning [letter]. BMJ 2001; 322: 106
16. Goldenberg SL. Prostatism: nature of the symptoms. Can J Urol 1997; 4 Suppl. 1: 3-5
17. Bostwick DG. Prostatic intraepithelial neoplasia (PIN): current concepts. J Cell Biochem 1992; 16H: 10-9
18. Silverman WM. J Am Osteopath Assoc 2004; 104 (2 Suppl. 2): S1-4
19. Abrams P. LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms [editorial]. Rev Urol 1999; 1: 65
20. Burnstock G. Cholinergic, adrenergic, and purinergic neuromuscular transmission. Fed Proc 1977; 36: 2434-8
21. Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-6
22. Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267-73
23. Chaikin DC, Blaivas JG. Voiding dysfunction: definitions. Curr Opin Urol 2000; 11:395-8
24. Novara G, Galfano A, Ficarra V, et al. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006; 50: 675-83
25. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006; 147 Suppl. 2: S25-40
26. Schafer W, Abrams P, Liao L, et al. International Continence Society. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002; 21: 261-74
27. Mazzucco R. American Urological Association: 96th Annual Meeting; 2001 Jun 2-7; Anaheim (CA). IDrugs 2001; 4: 892-5
28. Porru D, Bartoletti R, Austoni E, et al. Relationship of flow rate with symptoms, quality of life and other clinical parameters in patients with LUTS suggestive of BPH. Eur Urol 2001; 40 Suppl. 1: 23-7
29. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14; discussion 1314-15
30. Guay AT. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol Metab Clin North Am 2007; 36: 453-63
31. Polloack JS, Fostermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium derived relaxing factor syntase from cultured and native bovive aortic cells. Proc Natl Acad Sci U S A 1991; 88: 10480-4
32. Bivalacqua TJ, Musicki B, Usta MS, et al. Endothelial nitric oxide syntase gene therapy for erectile dysfunction. Curr Pharm Design 2005; 11: 4059-67
33. El Melegy NT, Ali ME, Awad EM. Plasma levels of endothelin-1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int 2005; 96: 1079-86
34. Clement P, Bernabe J, Kia HK, et al. D2-like receptors mediate the expulsion phase of ejaculation elicited by 8-hydroxy-2-(di-N-propylamino) tetralin in rats. J Pharmacol Exp Ther 2006; 316: 830-4
35. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-13
36. Rosen RC, Seidman SN, Menza MA, et al. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004; 16: 334-40
37. Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007; 4: 368-78
38. Russell S, McVary KT. Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man. Curr Urol Rep 2005; 6: 445-53
39. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998; 160: 1358-67
40. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193-202
41. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002; 19: 390-6
42. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003; 169: 1520-5
43. Paick JS, Ku JH, Shin JW, et al. Alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. BJU Int 2006; 97: 1017-23
44. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174 (4 Pt 1): 1334-8
45. Chapple CR, Carter P, Christmas TJ, et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-6
46. De Rose AF, Carmignani G, Corbu C, et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002; 68: 95-8
47. Kirby RS, Andersen M, Gratzke P, et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin- gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200
48. Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-87
49. Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2006; 8 Suppl. 4: S3-9
50. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 2007; 29: 17-25
51. Nishino Y, Masue T, Miwa K, et al. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 2006; 97: 747-51; discussion 751
52. McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol 2006; 175: 35-42
53. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717-23
54. Elhilali M, Emberton M, Matzkin H, et al. Long-term efficacy and safety of alfuzosin 10mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2006; 97: 513-9
55. Blue DR, Daniels DV, Gever JR, et al. Pharmacological characteristics of Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. BJU Int 2004; 93: 162-70
56. Sugaya K, Nishijima S, Miyazato M, et al. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002; 328: 74-6
57. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170 (2 Pt 1): 530-47
58. Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996; 119: 797-803
59. Schulman C. Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis 2001; 4 Suppl. 1: S12-6
60. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006; 28: 13-25
61. van Moorselaar RJ, Hartung R, Emberton M, et al. ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603-8
62. Kaminetsky J. Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin 2006; 22: 2497-506
63. Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997; 157: 525-30
64. Bartsch G, Fitzpatrick JM, Schalken JA, et al. Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 2004; 93 Suppl. 1: 27-9
65. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-62
66. Roehrborn CG, Bartsch G, Kirby R, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; 58: 642-50
67. AUA Guidelines on Management of Benign Prostatic Hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530-47
68. Johnson 2nd TM, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003; 170: 145-8
69. Roehrborn CG. The clinical benefits of dutasteride treatment for LUTS and BPH. Rev Urol 2004; 6 Suppl. 9: S22-30
70. Steers WD. 5alpha-reductase activity in the prostate. Urology 2001; 58: 17-24
71. Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 1999; 53: 690-5
72. O'Leary MP, Roehrborn C, Andriole G, et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003; 92: 262-6
73. Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-6
74. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98
75. Bales GT, Christiano AP, Kirsh EJ, et al. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University cof Chicago. Urology 1999; 54: 86-9
76. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604-9
77. Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am 2002; 29: 23-9
78. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 2002; 3: 285-91
79. Zlotta AR, Teillac P, Raynaud JP, et al. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 2005; 48: 269-76
80. Debruyne F, Koch G, Boyle P, et al. Groupe d'etude PERMAL. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study [in French]. Prog Urol 2002; 12: 384-92; discussion 394
81. Vela-Navarrete R, Escribano-Burgos M, Farre AL, et al. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol 2005; 173: 507-10
82. Wadsworth TL, Carroll JM, Mallinson RA, et al. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 2004; 145: 3205-14
83. Arruzazabala ML, Mas R, Carbajal D, et al. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on in vitro and in vivo effects mediated by alpha-adrenoceptors in rats. Drugs 2005; 6: 281-9
84. Agartan CA, Whitbeck C, Sokol R, et al. Protection of urinary bladder function by grape suspension. Phytother 2004; 18: 1013-8
85. Bloch W, Klotz T, Loch C, et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997; 33: 1-8
86. Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 2000; 109: 654-64
87. Levin RM, Whitbeck C, Horan P, et al. Low-dose tadenan protects the rabbit bladder from bilateral ischemia/reperfusion-induced contractile dysfunction. Phytomedicine 2005; 12 (1-2): 17-24
88. Yoshimura Y, Yamaguchi O, Bellamy F, et al. Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. Urology 2003; 61: 474-8
89. Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. Rev Urol 2003; 5 Suppl. 5: S28-35
90. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838-45
91. Hedlund P. Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract-is there a basis for pharmacological targeting of cGMP? World J Urol 2005; 23: 362-7
92. Deng CH, Chen HR, Qiu SP, et al. Effect of nitric oxide donor and alpha1-receptor antagonist on proliferation/apoptosis of hyperplastic prostatic stromal cells in vitro. Zhonghua Wai Ke Za Zhi 2004; 42: 201-4
93. Klotz T, Mathers MJ, Bloch W, et al. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999; 31: 335-41
94. Deka DK, Brading AF. Nitric oxide activates glibenclamide-sensitive K+ channels in urinary bladder myocytes through a c-GMP-dependent mechanism. Eur J Pharmacol 2004; 492: 13-9
95. Kedia G, Uckert S, Scheller F, et al. In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 2006; 67: 1292-7
96. Gradini R, Realacci M, Ginepri A, et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999; 189: 224-9
97. Stothers L, Laher I, Christ GT. A review of the L-arginine: nitric oxide: guanylate cyclase pathway as a mediator of lower urinary tract physiology and symptoms. Can J Urol 2003; 10: 1971-80
98. Cellek S. Nitrergic-noradrenergic interaction in penile erection: a new insight into erectile dysfunction. Drugs Today (Barc) 2000; 36: 135-46
99. Ventura S, Pennefather J, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002; 94: 93-112
100. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005; 40 (3): 121-8
101. Kim NN, Dhir V, Azadzoi KM, et al. Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction. J Androl 2002; 23: 76-83
102. Wingard CJ, Lewis R, Mills TM. Erection and NO override the vasoconstrictive effect of alpha-adrenergic stimulation in the rat penile vasculature. Int J Impot Res 2001; 13: 212-20
103. Filippi S, Marini M, Vannelli GB, et al. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum. Mol Hum Reprod 2003; 9: 765-74
104. Wingard CJ, Husain S, Williams J, et al. RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1145-52
105. Andersson KE. Detrusor contraction. Scand J Urol Nephrol Suppl 2004; 215: S54-7
106. Teixeira CE, Ying Z, Webb RC. Proerectile effects of the Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152) in the rat penis. J Pharmacol Exp Ther 2005; 315: 155-62
107. Chang S, Hypolite JA, Zderic SA, et al. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1124-30
108. Kajioka S, Nakayama S, McCoy R, et al. Inward current oscillation underlying tonic contraction caused via ETA receptors in pig detrusor smooth muscle. Am J Physiol Renal Physiol 2004; 286: F77-85
109. Wada Y, Latifpour J, Sanematsu H, et al. Age-related changes in contractile responses of rabbit lower urinary tract to endothelin. J Urol 2000; 164: 806-13
110. Imajo C, Walden PD, Shapiro E, et al. Evaluation of the effect of endothelin-1 and characterization of the selective endothelin a receptor antagonist PD155080 in the prostate. J Urol 1997; 158: 253-7
111. Wu-Wong JR, Chiou WJ, Saeed B, et al. Endothelin receptor in benign prostatic hyperplastic cells: binding and functional studies. Recept Signal Transduct 1997; 7: 165-75
112. Donoso MV, Salas C, Sepulveda G, et al. Involvement of ETA receptors in the facilitation by endothelin-1 of non-adrenergic non-cholinergic transmission in the rat urinary bladder. Br J Pharmacol 1994; 111: 473-82
113. Raschack M, Gock S, Unger L, et al. LU 302 872 and its racemate (LU 224 332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions. J Cardiovasc Pharmacol 1998; 31: S241-4
114. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005; 103: 9-17
115. Michaelson MD, Kaufman DS, Kantoff P, et al. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006; 107: 530-5
116. Rees RW, Foxwell NA, Ralph DJ, et al. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170 (6 Pt 1): 2517-22
117. Takahashi R, Nishimura J, Hirano K, et al. Ca2+ sensitization in contraction of human bladder smooth muscle. J Urol 2004; 172: 748-52
118. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 2004; 101: 9121-6
119. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn 2007; 26 Suppl. 6: 948-54
120. Calvert RC, Mumtaz FH, Dashwood MR, et al. Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl. Clin Sci (Lond) 2002; 103 Suppl. 48: 459-63S
121. Hall IP. Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br J Clin Pharmacol 1993; 35: 1-7
122. Tinel H, Stelte-Ludwig B, Hutter J, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1259-63
123. Uckert S, Kuthe A, Jonas U, et al. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-90
124. Qiu Y, Kraft P, Craig EC, et al. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 2002; 59: 145-9
125. Maurice DH, Palmer D, Tilley DG, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003; 64: 533-46
126. Dokita S, Smith SD, Nishimoto T, et al. Involvement of nitric oxide and cyclic GMP in rabbit urethral relaxation. Eur J Pharmacol 1994; 266: 269-75
127. Uckert S, Oelke M, Stief CG, et al. Immunohistochemical Distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006; 49: 740-5
128. Giuliano F, Kaplan SA, Cabanis MJ, et al. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006; 67: 1199-204
129. Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276-81
130. Grimsley SJ, Khan MH, Jones GE. Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007; 69: 25-6
131. Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836-9
132. Mulhall JP, Guhring P, Parker M, et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-7
133. McVary KT, Monnig W, Camps Jr JL, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071-7
134. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-7